ExodusPoint Capital Management’s Dyne Therapeutics DYN Stock Holding History

ExodusPoint Capital Management’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-46,270	Closed	-$440K	–	1660
2025 Q2	$440K	Sell	46,270 -72,599	-61%	-$799K	﹤0.01%	1178
2025 Q1	$1.24M	Buy	+118,869	New	+$1.7M	0.01%	862
2023 Q4	–	Sell	-184,010	Closed	-$1.65M	–	1602
2023 Q3	$1.65M	Buy	184,010 +149,526	+434%	+$1.61M	0.02%	747
2023 Q2	$388K	Buy	34,484 +8,472	+33%	+$99.9K	﹤0.01%	1446
2023 Q1	$300K	Buy	+26,012	New	+$338K	﹤0.01%	1469
2020 Q4	–	Sell	-78,448	Closed	-$1.58M	–	2051
2020 Q3	$1.58M	Buy	+78,448	New	+$1.72M	0.03%	482

Other funds holding DYN

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

ExodusPoint Capital Management's DYN Position: Q3 2025 in Review

ExodusPoint Capital Management sold out of Dyne Therapeutics (DYN) in Q3 2025, closing a stake of 46,270 shares — an estimated $440K sold.

ExodusPoint Capital Management first reported a position in DYN in Q3 2020 and held it in 6 quarters. The position peaked at $1.65M in Q3 2023. 207 funds tracked by Wall St. Rank hold DYN as of Q3 2025.

ExodusPoint Capital Management reported no remaining Dyne Therapeutics position as of Q3 2025 after selling out during the quarter.
ExodusPoint Capital Management sold 46,270 Dyne Therapeutics shares in Q3 2025, an estimated $440K.
ExodusPoint Capital Management first reported a position in Dyne Therapeutics in Q3 2020 and held it in 6 quarters.
ExodusPoint Capital Management's Dyne Therapeutics position peaked at $1.65M in Q3 2023.
207 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q3 2025.

Based on ExodusPoint Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.